Overview

Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bortezomib together with carboplatin works in treating patients with metastatic pancreatic cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with carboplatin may kill more tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Bortezomib
Carboplatin